期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 21, 期 2-3, 页码 185-195出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2010.02.011
关键词
Parvoviruses; Oncosuppression; Oncolysis; Immunomodulation; Cancer immunotherapy; Cancer virotherapy; Clinical trial
资金
- Helmholtz Gemeinschaft Deutscher Forschungszentren
- Deutsches Krebsforschungszentrum
- Institut National de la Sante et de la Recherche Medicale
- Institut National du Cancer
- University of Heidelberg
- German-Israeli Foundation for Scientific Research and Development
- Oryx GmbH
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据